previous
healthi
woman
present
stanford
univers
medic
center
palo
alto
ca
decemb
histori
fever
product
cough
hemoptysi
night
sweat
myalgia
three
day
prior
admiss
treat
outpati
oral
azithromycin
presumpt
communityacquir
pneumonia
symptom
worsen
despit
treatment
patient
live
norway
prior
move
california
octob
laboratori
research
deni
occup
exposur
infecti
agent
pet
cat
cigarett
smoker
cowork
also
recent
ill
respiratori
tract
infect
admiss
patient
temperatur
rest
oxygen
satur
decreas
movement
leukocyt
count
neutrophil
chest
radiograph
reveal
bilater
reticulonodular
infiltr
figur
ct
angiogram
reveal
diffus
bronchiol
figur
patient
treat
ceftriaxon
doxycyclin
place
respiratori
droplet
isol
result
initi
laboratori
test
includ
blood
sputum
cultur
rheumatoid
factor
antinuclear
antibodi
neg
day
hospit
admiss
patient
underw
bronchoscopi
reveal
mild
edema
hyperem
bronchiol
result
immunofluoresc
test
pneumocysti
jiroveci
neg
bacteri
fungal
acidfast
bacilli
cultur
bronchoalveolar
lavag
fluid
sampl
shell
vial
assay
cytomegaloviru
cytomegaloviru
pcr
bronchoalveolar
lavag
fluid
specimen
also
yield
neg
result
direct
fluoresc
antibodi
test
bronchoalveolar
lavag
fluid
use
respiratori
viru
screen
id
kit
diagnost
hybrid
fail
detect
respiratori
syncyti
viru
adenoviru
influenzaviru
b
parainfluenzaviru
type
likewis
viral
bronchoalveolar
lavag
fluid
cultur
use
rhesu
monkey
kidney
cell
line
human
fibroblast
cell
line
continu
human
alveolar
epitheli
cell
line
fail
demonstr
cytopath
effect
hemadsorpt
despit
incub
day
bronchoscopi
patient
becam
depend
mechan
ventil
pressor
serial
chest
radiograph
reveal
persist
bilater
infiltr
figur
antimicrobi
therapi
chang
moxifloxacin
oseltamivir
highdos
methylprednisolon
therapi
initi
result
viral
direct
fluoresc
antibodi
test
respiratori
virus
viral
cultur
perform
endotrach
aspir
specimen
obtain
day
hospit
admiss
neg
nose
swab
viral
cultur
perform
day
also
neg
day
hospit
admiss
given
critic
ill
condit
persist
unexplain
respiratori
failur
patient
underw
diagnost
openlung
biopsi
histopatholog
analysi
reveal
organ
bronchiol
without
granuloma
multinucl
giant
cell
viral
nuclear
inclus
figur
patholog
primarili
bronchiolocentr
lumen
bronchiol
fill
granul
tissu
plug
eosinophil
featur
typic
vascul
cryptogen
organ
pneumonia
acut
bronchopneumonia
patient
improv
clinic
continu
support
care
day
hospit
admiss
wean
mechan
ventil
discharg
day
hospit
admiss
addit
laboratori
studi
perform
cours
patient
hospit
fail
identifi
etiolog
ill
studi
includ
pcr
brochoalveolar
lavag
fluid
specimen
sever
acut
respiratori
syndrom
sar
coronaviru
metapneumoviru
well
pcr
direct
fluoresc
antibodi
test
nasopharyng
specimen
bordetella
pertussi
urin
test
legionella
antigen
serum
test
cryptococc
antigen
yield
neg
result
result
serolog
analys
hiv
infect
histoplasmosi
blastomycosi
tularemia
sporotrichosi
q
fever
leptospirosi
sin
nombr
hantaviru
infect
neg
serum
sampl
test
twice
patient
hospit
coccidioidomycosi
mycoplasma
chlamydia
antibodi
result
also
neg
ultim
diagnosi
made
examin
endotrach
aspir
hospit
day
use
virochip
assay
find
microarray
indic
presenc
confirm
subsequ
specif
pcr
serolog
analysi
clinic
specimen
collect
microarray
screen
day
hospit
admiss
endotrach
aspir
specimen
patient
collect
steril
cup
contain
viral
cultur
medium
mem
nissui
corpor
store
sampl
use
studi
obtain
accord
protocol
approv
stanford
univers
institut
review
board
total
rna
obtain
ml
sampl
extract
use
rnabe
isotex
diagnost
reversetranscrib
cdna
amplifi
modifi
round
ab
random
pcr
method
hybrid
virochip
previous
describ
virochip
scan
axon
scanner
axon
instrument
genepix
softwar
version
ncbi
geo
seri
thirdgener
virochip
use
ncbi
geo
platform
oligonucleotid
design
use
partial
sequenc
fullysequenc
genom
deposit
genbank
databas
june
sequenc
major
expans
previou
secondgener
chip
oligonucleotid
design
use
fullysequenc
refer
genom
sequenc
importantli
studi
new
microarray
design
incorpor
partial
sequenc
inform
paramyxovirida
speci
complet
genom
sequenc
avail
microarray
analysi
perform
rank
highest
intens
viral
oligonucleotid
zscore
zscore
specif
oligonucleotid
defin
distanc
sd
oligonucleotid
intens
median
intens
across
array
databas
perform
date
n
microarray
confirm
pcr
serolog
analysi
microarray
evid
confirm
pcr
amplifi
cdna
patient
endotrach
aspir
follow
sequenc
previous
publish
primer
use
amplifi
segment
genom
correspond
nucleoprotein
phosphoprotein
matrix
gene
new
primer
set
also
design
amplifi
conserv
region
within
gene
code
fusion
protein
larg
protein
degener
primer
deriv
clustalw
sequenc
align
fusion
gene
parainfluenza
parainfluenza
mump
virus
wherea
primer
deriv
sequenc
larg
protein
gene
reaction
contain
pcr
buffer
invitrogen
corpor
mmoll
mmoll
deoxyribonucleosid
triphosph
forward
primer
revers
primer
platinum
taq
dna
polymeras
invitrogen
corpor
templat
cdna
cycl
paramet
follow
min
initi
denatur
follow
cycl
denatur
anneal
elong
final
extens
min
appropri
posit
neg
control
includ
reaction
amplifi
pcr
band
expect
size
sequenc
abi
prism
dna
analyz
appli
biosystem
sequenc
compar
entri
genbank
databas
use
blast
algorithm
specif
serolog
analysi
use
indirect
immunofluoresc
assay
perform
accord
establish
protocol
previous
report
slide
prepar
primari
monkey
kidney
cell
product
infect
human
parainfluenzaviru
use
immunofluoresc
assay
broadrang
pcr
lung
biopsi
tissu
dna
extract
freshfrozen
lung
tissu
use
qiaamp
dna
mini
kit
qiagen
broadrang
bacteri
fungal
rdna
pcr
perform
extract
dna
use
bacteri
primer
fungal
primer
reaction
contain
pcr
bufferii
appli
biosystem
mmoll
triton
mmoll
tetramethylammonium
chlorid
mmoll
deoxyribonucleosid
triphosph
forward
primer
revers
primer
amplitaq
dna
polymeras
appli
biosystem
templat
dna
cycl
paramet
follow
min
initi
denatur
follow
cycl
denatur
anneal
elong
final
extens
min
mock
extract
control
includ
throughout
tissu
lysi
pcr
amplifi
product
verifi
gel
electrophoresi
use
agaros
gel
convent
diagnost
test
result
neg
virochip
panvir
dna
microarray
use
screen
possibl
infecti
agent
tradit
method
microarray
analysi
includ
visual
inspect
hierarch
cluster
visual
inspect
involv
examin
viral
ident
oligonucleotid
highest
intens
wherea
hierarch
cluster
use
set
microarray
group
oligonucleotid
similar
intens
profil
identifi
pattern
may
correspond
particular
viru
neither
visual
inspect
hierarch
cluster
detect
convinc
viral
signatur
microarray
thu
use
new
data
analysi
method
zscore
metric
implement
laboratori
identifi
weak
viral
signatur
zscore
metric
estim
statist
signific
individu
oligonucleotid
microarray
manual
inspect
top
viral
oligonucleotid
rank
zscore
reveal
possibl
paramyxoviru
signatur
paramyxovirida
oligonucleotid
among
top
zscore
rang
figur
four
oligonucleotid
deriv
human
parainfluenzaviru
human
parainfluenzaviru
simian
parainfluenzaviru
close
rel
oligonucleotid
map
differ
region
genom
correspond
nucleocapsid
protein
phosphoprotein
fusion
protein
larg
protein
figur
microarray
find
confirm
pcr
amplifi
cdna
obtain
patient
endotrach
aspir
specimen
pcr
use
primer
direct
fusion
gene
yield
pair
fragment
sequenc
found
share
nucleotid
ident
amino
acid
ident
correspond
region
genbank
databas
figur
sequenc
nucleoprotein
phosphoprotein
matrix
larg
protein
gene
also
obtain
pcr
figur
fragment
share
nucleotid
ident
avail
sequenc
genbank
databas
includ
nucleotid
ident
matrix
conserv
region
genom
figur
c
diagnosi
infect
confirm
examin
antibodi
titer
patient
serum
sampl
collect
day
symptom
onset
use
indirect
immunofluoresc
assay
figur
specif
antibodi
respons
observ
increas
igg
day
day
igg
titer
remain
elev
week
symptom
onset
patient
convalesc
phase
contrast
result
convalescentphas
serolog
analysi
parainfluenzaviru
type
perform
week
neg
igg
antibodi
titer
complement
fixat
broadrang
pcr
extract
lung
biopsi
dna
use
univers
bacteri
fungal
primer
also
neg
report
case
infect
previous
healthi
adult
present
lifethreaten
febril
respiratori
ill
key
identifi
examin
broader
rang
viral
pathogen
typic
standard
clinic
laboratori
virochip
particularli
wellsuit
purpos
allow
unbias
detect
genom
known
viral
famili
singl
assay
although
virochip
experiment
research
tool
potenti
applic
new
technolog
demonstr
rapid
comprehens
screen
put
viral
pathogen
acut
clinic
set
patient
alreadi
receiv
antibiot
time
admiss
neg
cultur
result
rule
concomit
bacteri
fungal
infect
howev
neg
result
broadrang
pcr
lung
biopsi
dna
use
univers
bacteri
fungal
primer
argu
possibl
furthermor
overal
clinic
pictur
viruslik
upper
respiratori
infect
prodrom
bilater
reticulonodular
pulmonari
infiltr
bronchiol
bronchoscopi
steadi
diseas
progress
despit
administr
broadspectrum
antibiot
consist
sever
viral
bronchiolitispneumon
bacteri
pneumonia
identifi
potenti
candid
pathogen
microarray
subsequ
pcr
endotrach
aspir
sampl
collect
day
hospit
admiss
longitudin
studi
children
suggest
human
parainfluenzavirus
shed
oropharynx
long
week
thu
surpris
still
abl
detect
specimen
collect
day
hospit
admiss
correspond
day
symptom
onset
nosocomi
infect
remot
possibl
although
studi
patient
receiv
diagnosi
acut
viral
pneumonia
intens
care
unit
reveal
nearli
ill
commun
acquir
moreov
patient
igg
antibodi
titer
alreadi
elev
day
hospit
admiss
make
nosocomi
infect
extrem
unlik
despit
extens
microbiolog
test
pathogen
identifi
patient
case
document
seroconvers
accompani
clinic
infect
provid
strong
addit
support
viru
etiolog
agent
patient
ill
primarili
associ
mild
upper
respiratori
infect
children
adult
although
serolog
evid
suggest
may
account
respiratori
tract
infect
clinic
signific
immunocompet
individu
unknown
diagnosi
infect
problemat
difficult
isol
viral
cultur
standard
commerci
direct
fluoresc
antibodi
panel
avail
clinic
virolog
laboratori
includ
rare
instanc
shown
caus
sever
respiratori
diseas
children
immunocompromis
individu
hitherto
associ
acut
respiratori
failur
healthi
young
adult
case
expand
document
clinic
spectrum
infect
support
specif
test
individu
unexplain
critic
respiratori
ill
